Non-coding RNA

Testis - Specific Gene Involved in Sex Ratio Regulation Discovered by Researchers from the Gwangju Institute of Science & Technology

Retrieved on: 
Friday, July 30, 2021

While many lncRNA genes have been identified, determining their specific purposes remains a challenge.

Key Points: 
  • While many lncRNA genes have been identified, determining their specific purposes remains a challenge.
  • At Professor Chunghee Cho's lab in the Gwangju Institute of Science and Technology in Korea, a team of scientists has recently discovered a novel lncRNA gene relevant to a crucial topic in life sciences: the regulation of sex ratios for offspring.
  • Then, to gain insight into the function of Teshl, the researchers genetically engineered mice that lacked this gene.
  • In turn, these genes are important for the correct development of Y-bearing sperm and the proper regulation of certain X chromosome-specific genes.

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

Retrieved on: 
Tuesday, July 27, 2021

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics CRISPR/Cas9 patent portfolio.
  • We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings, said Eric Rhodes, CEO of ERS Genomics.
  • Japan SLCs animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.
  • We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.

Premier, Inc. to Report Fiscal 2021 Fourth-Quarter and Full-Year Results and Host Conference Call on August 17, 2021

Retrieved on: 
Wednesday, July 14, 2021

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 fourth quarter and full year on Tuesday, August 17, 2021, at approximately 6:30 a.m. EDT.

Key Points: 
  • Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 fourth quarter and full year on Tuesday, August 17, 2021, at approximately 6:30 a.m. EDT.
  • The company will also host a conference call at 8:00 a.m. EDT to discuss its financial results.
  • The conference call will be webcast live from the company's website and available at the following link: PINC Webcast Link .
  • The webcast should be accessed 10 minutes prior to the conference call start time.

Comprehensive Foodomics Research Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021

The "Comprehensive Foodomics" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Comprehensive Foodomics" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.
  • Comprehensive Foodomics offers a definitive collection of over 150 articles that provide researchers with innovative answers to crucial questions relating to food quality, safety and its vital and complex links to our health.
  • Topics covered include transcriptomics, proteomics, metabolomics, genomics, green foodomics, epigenetics and noncoding RNA, food safety, food bioactivity and health, food quality and traceability, data treatment and systems biology.
  • Logically structured into 10 focused sections, each article is authored by world leading scientists who cover the whole breadth of Omics and related technologies, including the latest advances and applications.

HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs

Retrieved on: 
Thursday, May 20, 2021

b'HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.

Key Points: 
  • b'HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
  • HAYA is preparing to initiate clinical trials with its Wisper targeting candidate in non-obstructive hypertrophic cardiomyopathy, an orphan indication with limited treatment options.
  • Additionally, Jens Eckstein, Ph.D., Managing Partner at Apollo Health Ventures, and Benjamin Kreitman of Broadview Ventures will join HAYA\xe2\x80\x99s board.
  • With teams in Berlin and Boston AHV builds and invests in emerging and cutting-edge geroscience companies globally.

Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

Retrieved on: 
Friday, May 7, 2021

The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.

Key Points: 
  • The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
  • Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.\nVisit adnas.com for more information.
  • Follow us on Twitter and LinkedIn .
  • Join our mailing list .\nApplied DNA is a member of the Russell Microcap\xc2\xae Index.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005087/en/\n'

Development of Gene Editing Tools for Treating Genetic Diseases to Present Immense Growth Opportunities for Synthetic Biology Market, Growth Projected at whopping 26.3% CAGR from 2019 to 2027, TMR

Retrieved on: 
Wednesday, April 21, 2021

Public agencies in many nations, including EU countries,Finland, the UK, China,the US, andSingaporehave formed road maps and otherrelated developmentalframeworks.

Key Points: 
  • Public agencies in many nations, including EU countries,Finland, the UK, China,the US, andSingaporehave formed road maps and otherrelated developmentalframeworks.
  • Private funding in synthetic biology is also continuing to grow at a considerable rate, as per the Science X news portal.
  • The CRISPR (clustered regularly spread short palindromic repeats) refers toa method utilised to modify genomes, which has revolutionised synthetic biology.
  • This, in turn, is likely to work in favor of the global synthetic biology market in the years to come.

Development of Gene Editing Tools for Treating Genetic Diseases to Present Immense Growth Opportunities for Synthetic Biology Market, Growth Projected at whopping 26.3% CAGR from 2019 to 2027, TMR

Retrieved on: 
Wednesday, April 21, 2021

Public agencies in many nations, including EU countries,Finland, the UK, China,the US, andSingaporehave formed road maps and otherrelated developmentalframeworks.

Key Points: 
  • Public agencies in many nations, including EU countries,Finland, the UK, China,the US, andSingaporehave formed road maps and otherrelated developmentalframeworks.
  • Private funding in synthetic biology is also continuing to grow at a considerable rate, as per the Science X news portal.
  • The CRISPR (clustered regularly spread short palindromic repeats) refers toa method utilised to modify genomes, which has revolutionised synthetic biology.
  • This, in turn, is likely to work in favor of the global synthetic biology market in the years to come.

Study Demonstrates Elucid’s Ability to Estimate RNA Expression from Non-Invasive Cardiovascular Imaging

Retrieved on: 
Monday, March 22, 2021

The study entitled Virtual Transcriptomics, demonstrates a first-of-its-kind estimation of coding and non-coding RNA transcripts from a CT angiography using Elucids software.

Key Points: 
  • The study entitled Virtual Transcriptomics, demonstrates a first-of-its-kind estimation of coding and non-coding RNA transcripts from a CT angiography using Elucids software.
  • The promise of this work is to enable true precision medicine for cardiovascular disease.
  • This innovative study demonstrates the potential of computed tomography-based Virtual Transcriptomics to non-invasively predict gene expression, which opens up the field to potential new therapeutic approaches.
  • Elucids plaque morphology capabilities have already been used to demonstrate efficacy of numerous cardiovascular therapeutics; the addition of expression holds significant promise.

aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

Retrieved on: 
Friday, January 22, 2021

Research approach led to the identification of target receptors for two tRNA synthetases and further validates companys biology platform.

Key Points: 
  • Research approach led to the identification of target receptors for two tRNA synthetases and further validates companys biology platform.
  • The poster describes a mass spectrometry proteomics-based approach to identify target receptors for two distinct extracellular tRNA synthetase fragments.
  • Furthermore, this approach can be applied more broadly to identify receptor targets of extracellular proteins and other ligands such as peptides, antibodies or viruses.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.